Insights Into Acute Myeloid Leukemia (AML) Southeast

Perspectives on management of newly diagnosed and relapsed/refractory AML

Southeast June 22, 2020

Faculty Chair

Naval Daver, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • The objective of the report is to gain advisors’ perspectives on the management of newly diagnosed and relapsed/refractory (R/R) acute myeloid leukemia (AML)
  • A moderated, virtual roundtable discussion focusing on treatment of AML was held on June 22, 2020
  • Insights on the following AML therapies were obtained: azacitidine, cytarabine and daunorubicin (ie, 7+3), decitabine, ivosidenib, enasidenib, gemtuzumab ozogamicin, gilteritinib, liposomal daunorubicin and cytarabine, midostaurin, sorafenib, venetoclax, and glasdegib
  • Data collection was accomplished through use of audience response system (ARS) questioning and in-depth moderated discussion

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Disease state and data presentations were developed in conjunction with Dr Naval Daver from MD Anderson Cancer Center
  • The group of advisors comprised of community oncologists from the Southeast
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.